• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

作者信息

Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, Martelli M F, Stein H

机构信息

Institute of Hematology, University of Perugia, Italy.

出版信息

Blood. 1995 Jan 1;85(1):1-14.

PMID:7803786
Abstract
摘要

相似文献

1
CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.CD30（Ki-1）分子：肿瘤坏死因子受体超家族的一种新型细胞因子受体，作为诊断和免疫治疗的工具
Blood. 1995 Jan 1;85(1):1-14.
2
Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).来自霍奇金淋巴瘤类似细胞系L540的可溶性CD30形式的脱落受到一种新型CD30特异性抗体（Ki-4）的强烈抑制。
Int J Cancer. 1995 Feb 8;60(4):539-44. doi: 10.1002/ijc.2910600419.
3
Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.霍奇金淋巴瘤和非霍奇金淋巴瘤的免疫组织化学，重点关注BNH9抗体与间变性大细胞（CD30阳性）淋巴瘤反应性的诊断意义。
Cancer. 1992 Dec 1;70(11):2691-8. doi: 10.1002/1097-0142(19921201)70:11<2691::aid-cncr2820701121>3.0.co;2-2.
4
Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.利用针对CD30抗原的高亲和力单克隆抗体，开发对人霍奇金细胞具有强效体外抗肿瘤作用且对SCID小鼠播散性霍奇金肿瘤有效的新型蓖麻毒素A链免疫毒素。
Int J Cancer. 1995 Oct 9;63(2):238-44. doi: 10.1002/ijc.2910630216.
5
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.抗CD30单克隆抗体（MDX-060）用于霍奇金淋巴瘤和间变性大细胞淋巴瘤的I/II期研究。
J Clin Oncol. 2007 Jul 1;25(19):2764-9. doi: 10.1200/JCO.2006.07.8972. Epub 2007 May 21.
6
MDX-060. Medarex.MDX - 060。麦迪雷克斯公司。
Curr Opin Investig Drugs. 2005 Dec;6(12):1266-71.
7
A sinusoidal large cell lymphoma with expression of CD30, CD15, and multiple B-cell antigens: a classical Hodgkin lymphoma with sinusoidal infiltrating pattern or a sinusoidal CD30 positive large B-cell lymphoma with CD15?
Leuk Lymphoma. 2010 Jun;51(6):1148-51. doi: 10.3109/10428194.2010.480820.
8
CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.CD30配体是肿瘤坏死因子配体超家族的成员之一，可调控CD30+淋巴细胞和淋巴瘤细胞的生长与活化。
Leuk Lymphoma. 1996 Feb;20(5-6):397-409. doi: 10.3109/10428199609052421.
9
Chimeric antigen receptor T-cell therapy targeting CD30 in Hodgkin lymphoma.靶向霍奇金淋巴瘤中CD30的嵌合抗原受体T细胞疗法。
Clin Adv Hematol Oncol. 2021 Jan;19(1):24-26.
10
CD30-positive cutaneous anaplastic large cell lymphoma with ichthyosis acquisita.伴有获得性鱼鳞病的CD30阳性皮肤间变性大细胞淋巴瘤
Tumori. 1999 Jan-Feb;85(1):71-4. doi: 10.1177/030089169908500116.

引用本文的文献

1
Molecular heterogeneity of CD30 peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study.具有预后意义和治疗意义的CD30外周T细胞淋巴瘤的分子异质性：一项回顾性多中心研究
EBioMedicine. 2025 May;115:105693. doi: 10.1016/j.ebiom.2025.105693. Epub 2025 Apr 10.
2
Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children's Oncology Group NHL Committee.儿童和青少年外周T细胞淋巴瘤，非特指型：来自儿童肿瘤学组非霍奇金淋巴瘤委员会的综述
Blood Adv. 2025 Mar 25;9(6):1420-1431. doi: 10.1182/bloodadvances.2024013689.
3
ALK + anaplastic large cell lymphoma involving the bladder: case report and review of the literature.
ALK阳性间变性大细胞淋巴瘤累及膀胱：病例报告及文献复习
Diagn Pathol. 2024 Dec 18;19(1):157. doi: 10.1186/s13000-024-01585-z.
4
Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.使用奥瑞珠单抗清除B细胞后，多发性硬化症中活化记忆B细胞的频率升高现象会恢复到健康对照水平。
J Neuroimmunol. 2025 Feb 15;399:578502. doi: 10.1016/j.jneuroim.2024.578502. Epub 2024 Dec 2.
5
CD30 influences germinal center B-cell dynamics and the expansion of IgG1-switched B cells.CD30 影响生发中心 B 细胞的动力学和 IgG1 转换 B 细胞的扩增。
Cell Mol Immunol. 2024 Dec;21(12):1410-1425. doi: 10.1038/s41423-024-01219-w. Epub 2024 Oct 17.
6
Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.癌症治疗中的抗体药物偶联物：作用机制与临床研究
MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug.
7
Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors.人工智能驱动的分子对接和导向分子动力学在抗 CD30 嵌合抗原受体 scFv 选择中的精确应用。
Int J Mol Sci. 2024 Jun 30;25(13):7231. doi: 10.3390/ijms25137231.
8
The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.工程化 CAR-T 细胞与 PD-1 阻断联合免疫治疗在淋巴瘤和实体瘤中的协同作用：系统评价。
Front Immunol. 2024 May 10;15:1389971. doi: 10.3389/fimmu.2024.1389971. eCollection 2024.
9
Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.霍奇金淋巴瘤治疗的进展：从分子生物学到临床实践
Cancers (Basel). 2024 May 10;16(10):1830. doi: 10.3390/cancers16101830.
10
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin.原发性皮肤CD30阳性淋巴增殖性疾病——当前以维布妥昔单抗为重点的治疗方法
J Clin Med. 2024 Jan 31;13(3):823. doi: 10.3390/jcm13030823.